Video

Panel to discuss new data regarding TP53 mutations and prostate cancer risk

Author(s):

Urology Times staff

“Our case discussion for January 18 is going to be focused on a patient who initially has biochemically recurrent prostate cancer [and] progresses to metastatic disease,” says Veda N. Giri, MD.

In this video, Veda N. Giri, MD, offers a preview of the ENGAGEMENT Study Virtual Genetics Board’s upcoming case discussion focusing on new data on TP53 mutations and prostate cancer risk as well as TP53-related management. which you can sign up for by going to www.prostategenetics.com/engagement. The event will take place on January 18 at 12 pm ET. Giri is a Professor in Medical Oncology and Cancer Biology at Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania.

Related Videos
Karyn S. Eilber, MD, answers a question during a Zoom video interview
Woman at doctor | Image Credit: © rocketclips - stock.adobe.com
Perry Xu, MD, answers a question during Zoom video interview
Suzanne B. Merrill, MD, FACS, answers a question during a Zoom video interview
Related Content
Myriad Genetics, PATHOMIQ enter agreement for usage of AI platform for prostate cancer
February 25th 2025

Myriad Genetics, PATHOMIQ enter agreement for usage of AI platform for prostate cancer

Hannah Clarke
Myriad is planning to launch its first AI-driven prostate cancer clinical test later this year.
Pathogenic variants of WNT9B gene linked to hereditary prostate cancer
January 29th 2025

Pathogenic variants of WNT9B gene linked to hereditary prostate cancer

Hannah Clarke
WNT9B E152K was associated with a 2.5-fold increase in the risk of prostate cancer and reached genome-wide significance.
Genomic tests may offer valuable prognostic insights, but clinical utility remains unclear
January 22nd 2025

Genomic tests may offer valuable prognostic insights, but clinical utility remains unclear

Hannah Clarke
"[The] full integration [of genomic classifier tests] into clinical practice requires additional research to better understand their cost-effectiveness, clinical utility, and impact on diverse populations," says Amir Alishahi Tabriz, MD, PhD, MPH.
Prostate Gland - (BPH) Benign Prostatic Hyperplasia | Image Credit: © Judith - stock.adobe.com
December 26th 2024

Top 10 BPH articles and videos of 2024

Benjamin P. Saylor
As the year comes to a close, we revisit some of this year’s top content on benign prostatic hyperplasia.
3d rendered genetic illustration of human dna under microscope created with generative ai technology | Image Credit: © Picture Studio - stock.adobe.com
December 24th 2024

Quiz: CUA guidelines on specimen and timing considerations with genetic testing

Patrick Campbell
Test your knowledge of these often-overlooked but essential aspects of genetic and genomic testing.
NCCN reaffirms Prolaris’ prognostic value in prostate cancer
December 18th 2024

NCCN reaffirms Prolaris’ prognostic value in prostate cancer

Hannah Clarke
The inclusion of the test is supported by more than 25 studies demonstrating its clinical utility, including 2 studies published earlier this year.
© 2025 MJH Life Sciences

All rights reserved.